227 related articles for article (PubMed ID: 25351849)
1. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
[TBL] [Abstract][Full Text] [Related]
4. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
5. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
[TBL] [Abstract][Full Text] [Related]
6. Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.
Sakamoto S; Yamada T; Terazaki Y; Yoshiyama K; Sugawara S; Takamori S; Matsueda S; Shichijo S; Yamada A; Noguchi M; Itoh K; Hattori N; Kohno N; Sasada T
Clin Lung Cancer; 2017 Nov; 18(6):e385-e394. PubMed ID: 28416261
[TBL] [Abstract][Full Text] [Related]
7. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
Matsumoto K; Noguchi M; Satoh T; Tabata K; Fujita T; Iwamura M; Yamada A; Komatsu N; Baba S; Itoh K
BJU Int; 2011 Sep; 108(6):831-8. PubMed ID: 21166757
[TBL] [Abstract][Full Text] [Related]
9. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
11. Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Naitou M; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2017 Apr; 108(4):598-603. PubMed ID: 28178396
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
[TBL] [Abstract][Full Text] [Related]
13. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
Yamada T; Terazaki Y; Sakamoto S; Yoshiyama K; Matsueda S; Komatsu N; Waki K; Yamada A; Kawahara A; Kage M; Sugawara S; Yamashita Y; Sasada T; Takamori S; Itoh K
Int J Oncol; 2015 Jan; 46(1):55-62. PubMed ID: 25310280
[TBL] [Abstract][Full Text] [Related]
16. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
Kawano K; Tsuda N; Waki K; Matsueda S; Hata Y; Ushijima K; Itoh K; Yamada A; Kamura T
Cancer Sci; 2015 Sep; 106(9):1111-7. PubMed ID: 26122553
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
Hazama S; Takenouchi H; Tsunedomi R; Iida M; Suzuki N; Iizuka N; Inoue Y; Sakamoto K; Nakao M; Shindo Y; Kanekiyo S; Tokumitsu Y; Yoshimura K; Maeda N; Maeda K; Maeda Y; Matsui H; Yoshino S; Nakamura Y; Fujita Y; Hamamoto Y; Okamoto M; Fujita T; Kawakami Y; Oka M
Anticancer Res; 2014 Aug; 34(8):4201-5. PubMed ID: 25075047
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
[TBL] [Abstract][Full Text] [Related]
20. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.
Sato Y; Fujiwara T; Mine T; Shomura H; Homma S; Maeda Y; Tokunaga N; Ikeda Y; Ishihara Y; Yamada A; Tanaka N; Itoh K; Harada M; Todo S
Cancer Sci; 2007 Jul; 98(7):1113-9. PubMed ID: 17459063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
